The effects of empagliflozin on kidney function and glucose metabolism in acute kidney injury
- PMID: 40373495
- DOI: 10.1016/j.jclinane.2025.111865
The effects of empagliflozin on kidney function and glucose metabolism in acute kidney injury
Conflict of interest statement
Declaration of competing interest DHR has served as a consultant and received honoraria from Boehringer Ingelheim and Lilly, Merck, Novo Nordisk, Sanofi, and AstraZeneca. He has also received research operating funds from Boehringer Ingelheim and Lilly Diabetes Alliance, AstraZeneca, and Novo Nordisk; all honoraria are paid to his employer (Amsterdam University Medical Center, Amsterdam). All other authors declare no conflicts of interest.
Publication types
LinkOut - more resources
Full Text Sources